Yan

Milliman survey of fixed indexed and multi-year guaranteed annuity writers finds high lapse rates in 2023, adjustments to dynamic lapse formulas

Retrieved on: 
Thursday, February 29, 2024

Milliman, Inc., a premier global consulting and actuarial firm, today announced the findings of a new survey that explored dynamic lapse adjustments for annuity writers in the face of rising interest rates.

Key Points: 
  • Milliman, Inc., a premier global consulting and actuarial firm, today announced the findings of a new survey that explored dynamic lapse adjustments for annuity writers in the face of rising interest rates.
  • Milliman surveyed 13 fixed indexed annuity (FIA) and multi-year guaranteed annuity (MYGA) writers and asked them to weigh in on their actual lapse experience and expected lapse assumptions, dynamic lapse adjustments to base lapse rates (including the industry’s perception of the hypothetical competitor rate), limits to the dynamic adjustments, and the likelihood they might change their methodology.
  • The survey responses were combined with surrender analysis using policy data collected from 16 companies between January 2007 to March 2023.
  • “Our survey revealed high lapsation rates in general in 2023, with participants adjusting their dynamic lapse formulas to address experience over the past year,” said Nathan Wilbanks, Director of Marketing and Sales with Milliman’s Life and Annuity Predictive Analytics team.

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, February 7, 2024

Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.

Key Points: 
  • Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
  • The study provides seminal preclinical proof-of-concept data for the treatment of amyotrophic lateral sclerosis (ALS).
  • Most importantly, the validated ALS clinical biomarker neurofilament light chain (Nf-L) was reduced in line with the positive treatment effects.
  • TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration.

Shanghai Stonehill Technology Unveils the First Non-Attention-Based Large Model in China: Faster, Stronger, More Economical

Retrieved on: 
Friday, January 26, 2024

On January 24th, at the "New Architecture of Large Language Model", Rock AI (a subsidiary of Shanghai Stonehill Technology Co., Ltd.) officially unveiled the first domestic general-purpose large language model without an Attention mechanism—the Yan Model.

Key Points: 
  • On January 24th, at the "New Architecture of Large Language Model", Rock AI (a subsidiary of Shanghai Stonehill Technology Co., Ltd.) officially unveiled the first domestic general-purpose large language model without an Attention mechanism—the Yan Model.
  • It is also one of the rare large models in the industry that does not rely on a Transformer architecture.
  • Additionally, it supports lossless operation on CPUs, reduced hallucination in expressions, and 100% support for private deployment applications.
  • To address these issues, the Yan Model replaces the Transformer architecture with a newly developed generative "Yan Architecture" of its own.

NEW STATE CAPITAL PARTNERS ANNOUNCES NEW HIRES AND PROMOTION

Retrieved on: 
Thursday, January 4, 2024

NEW ROCHELLE, N.Y., Jan. 4, 2024 /PRNewswire/ -- New State Capital Partners ("New State") today announced it has hired Jason Levy as a Vice President and Yanre Wu as an Associate. It has also promoted Victoria Smorodinova to Vice President from Senior Associate. New State is a middle market private equity firm with over a decade of experience partnering with entrepreneurially minded management teams, typically as first institutional capital.

Key Points: 
  • NEW ROCHELLE, N.Y., Jan. 4, 2024 /PRNewswire/ -- New State Capital Partners ("New State") today announced it has hired Jason Levy as a Vice President and Yanre Wu as an Associate.
  • New State is a middle market private equity firm with over a decade of experience partnering with entrepreneurially minded management teams, typically as first institutional capital.
  • Most recently, Mr. Levy was a Vice President at AOS Capital and prior to that, held positions as a Senior Associate at Guardian Capital Partners and an Investment Banking Associate at Fairmount Partners.
  • Ms. Wu joins New State from BofA Securities, where she was an Associate in the Consumer and Retail Group.

Zhihu Inc. Reports Unaudited Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 29, 2023

BEIJING, Nov. 29, 2023 /PRNewswire/ -- Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended September 30, 2023.

Key Points: 
  • BEIJING, Nov. 29, 2023 /PRNewswire/ -- Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended September 30, 2023.
  • Total revenues were RMB1,022.2 million (US$140.1 million) in the third quarter of 2023, representing a 12.1% increase from the same period of 2022.
  • Net loss was RMB278.4 million (US$38.2 million) in the third quarter of 2023, narrowed by 6.5% from the same period of 2022.
  • "Our significant strides in commercialization and the vibrant dynamism across the Zhihu community once again drove sustainable business growth during the third quarter of 2023.

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)

Retrieved on: 
Wednesday, November 22, 2023

The NDA acceptance are based on positive results from the Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated taletrectinib in Chinese ROS1-positive NSCLC patients.

Key Points: 
  • The NDA acceptance are based on positive results from the Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated taletrectinib in Chinese ROS1-positive NSCLC patients.
  • I hope this NDA represents a step towards making another option available to the ROS1-positive NSCLC patient community in China."
  • Bing Yan, MD, Chief Medical Officer of AnHeart, stated: "Acceptance of our China NDA marks an important milestone for AnHeart and is the first regulatory submission for taletrectinib globally.
  • In June 2021, Innovent and AnHeart entered into an exclusive license agreement for the co-development and commercialization of taletrectinib in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

Semiconductor Research Corporation Recognizes Innovation and Excellence at their 25th TECHCON Networking Event

Retrieved on: 
Tuesday, September 12, 2023

Every year, Semiconductor Research Corporation honors excellence across the semiconductor research community with awards for industry professionals and university researchers.

Key Points: 
  • Every year, Semiconductor Research Corporation honors excellence across the semiconductor research community with awards for industry professionals and university researchers.
  • The Technical Excellence Award recognizes research of exceptional value to SRC members by significantly enhancing the productivity and competitiveness of the semiconductor industry.
  • The SRC Innovation Award recognizes patents and IP arising from SRC research that represent inventive approaches that have made a significant impact on the semiconductor industry.
  • Now in its 25th year, TECHCON is a unique event in the industry because it facilitates direct interaction between semiconductor industry professionals and SRC Research Scholars.

Zhihu Inc. Reports Unaudited Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 23, 2023

BEIJING, Aug. 23, 2023 /PRNewswire/ -- Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended June 30, 2023.

Key Points: 
  • BEIJING, Aug. 23, 2023 /PRNewswire/ -- Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended June 30, 2023.
  • Net loss was RMB279.1 million (US$38.5 million) in the second quarter of 2023, narrowed by 42.7% from the same period of 2022.
  • "In the second quarter of 2023, we continued to achieve high-quality growth and optimize our operating efficiency," said Mr. Yuan Zhou, chairman and chief executive officer of Zhihu.
  • Mr. Henry Sha, chief financial officer of Zhihu, added, "Our multi-engine business model delivered solid results this quarter with sustainable growth momentum.

Davis Polk Elects 12 New Partners

Retrieved on: 
Wednesday, July 5, 2023

Shanu Bajaj is a member of Davis Polk’s Mergers & Acquisitions practice in New York.

Key Points: 
  • Shanu Bajaj is a member of Davis Polk’s Mergers & Acquisitions practice in New York.
  • Sidney Bashago is a member of Davis Polk’s White Collar Defense & Investigations practice in New York.
  • Stephen Byeff is a member of Davis Polk’s Capital Markets practice in New York.
  • Lijun (Annie) Yan is a member of Davis Polk’s Corporate practice, currently practicing as a Registered Foreign Lawyer in Beijing.

Zhihu Inc. Reports Unaudited First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 24, 2023

BEIJING, May 24, 2023 /PRNewswire/ --  Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended March 31, 2023.

Key Points: 
  • BEIJING, May 24, 2023 /PRNewswire/ --  Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended March 31, 2023.
  • Net loss was RMB179.0 million (US$26.1 million) in the first quarter of 2023, narrowed by 70.9% from the same period in 2022.
  • "We are pleased to report a strong first quarter of 2023, with impressive revenue growth and another quarter of significantly narrowed loss.
  • Mr. Henry Sha, chief financial officer of Zhihu, added, "We outperformed this quarter by beating market consensus in terms of both top line and bottom line.